OmniaBio Inc. has expanded its footprint by adding a new process and analytical development lab space at the McMaster University Medical Centre (MUMC)…
OmniaBio expands manufacturing footprint with second Hamilton location Read More »
Avectas, a cell
engineering technology business and CCRM, with its subsidiary OmniaBio Inc., a CDMO
that enables the development of cell therapies and…
Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapies to treat advanced liver…
OmniaBio, CCRM and Stakeholders Celebrate Commencement of Construction of Hamilton Biomanufacturing Facility…
OmniaBio celebrates the beginning of construction Read More »
Next Generation Manufacturing Canada (NGen), the industry-led organization behind Canada’s Global Innovation Cluster for Advanced Manufacturing…
Ngen supports commercial scale manufacturing of cell and gene therapies in Canada Read More »
OmniaBio Inc., a subsidiary of CCRM, has executed a strategic agreement with Medipost, a global leader in stem cell therapeutics…
OmniaBio Inc. announces private investor Read More »
Invest Ontario is supporting OmniaBio Inc. in launching a new biomanufacturing facility that will catalyze Ontario life sciences jobs and innovation…
Invest Ontario supports new biomanufacturing facility in Hamilton Read More »
OmniaBio Inc., a subsidiary of CCRM, is the first project to be funded under the Invest Ontario Fund. Subject to reaching a definitive agreement, OmniaBio Inc…
Funding from Ontario Government for OmniaBio Read More »
